Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 4/20 | 0.47 |
| ▸ | MMP12 | P39900 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP7 | P09237 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CREB1 | P16220 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338935 | 0.87 | IDH1 (0.48) | IDH1MMP3MMP12MMP1MMP2 | |
| SCHEMBL338697 | 0.87 | IDH1 (0.50) | IDH1MMP3MMP12MMP1MMP2 | |
| SCHEMBL339006 | 0.85 | BRD4 (0.47) | IDH1MMP3MMP12MMP1MMP2 | |
| SCHEMBL13395924 | 0.85 | BRD4 (0.50) | IDH1MMP3MMP12MMP1MMP2 | |
| SCHEMBL338498 | 0.83 | MEN1 (0.50) | IDH1MMP3MMP12MMP1MMP2 | |
| SCHEMBL339672 | 0.83 | KMT2A (0.53) | IDH1HPGDSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL2984201 | 0.83 | MMP3 (0.72) | MMP3MMP12MMP1MMP2MMP7 | |
| SCHEMBL13208646 | 0.82 | MMP3 (0.59) | IDH1MMP3MMP12MMP1MMP2 | |
| SCHEMBL339133 | 0.82 | SGMS2 (0.54) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL14260034 | 0.82 | MMP3 (0.59) | MMP3MMP12MMP1MMP2MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687298-B1 | CYCLOALKYL DERIVATIVES OF 3-HYDROXY-4-PYRIDINONES | APOTEX INC (CA) | 2012-12-26 | — | — | EP | disclosed |
| EP-1824823-B1 | PROCESS FOR THE MANUFACTURE OF 3-HYDROXY-N-ALKYL-1-CYCLOALKYL-6-ALKYL-4-OXO-1,4-DIHYDROPYRIDINE-2-CARBOXAMIDE AND ITS RELATED ANALOGUES | APOTEX INC (CA) | 2012-04-25 | — | — | EP | disclosed |
| US-8097624-B2 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones | APOTEX INC. (CA) | 2012-01-17 | — | — | US | disclosed |
| US-7893269-B2 | amidation of 3-(benzyloxy)-1-cyclopropyl-6-methyl-4-oxo-1,4-dihydropyridine-2-carboxylic acid via the 2-acid chloride and then reaction with an amine; hydrolysis or catalytic hydrogenation to deprotect 3-hydroxy group; high yields for industrial application; the 3-(benzyloxy)-2-carboxamide intermediate | APOTEX INC (CA) | 2011-02-22 | — | — | US | disclosed |
| US-7893269-B2 | amidation of 3-(benzyloxy)-1-cyclopropyl-6-methyl-4-oxo-1,4-dihydropyridine-2-carboxylic acid via the 2-acid chloride and then reaction with an amine; hydrolysis or catalytic hydrogenation to deprotect 3-hydroxy group; high yields for industrial application; the 3-(benzyloxy)-2-carboxamide intermediate | APOTEX INC (CA) | 2011-02-22 | — | — | US | disclosed |
| US-7893269-B2 | amidation of 3-(benzyloxy)-1-cyclopropyl-6-methyl-4-oxo-1,4-dihydropyridine-2-carboxylic acid via the 2-acid chloride and then reaction with an amine; hydrolysis or catalytic hydrogenation to deprotect 3-hydroxy group; high yields for industrial application; the 3-(benzyloxy)-2-carboxamide intermediate | APOTEX INC (CA) | 2011-02-22 | — | — | US | disclosed |
| US-20090170850-A1 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones | APOTEX INC. | 2009-07-02 | — | — | US | disclosed |
| US-7410985-B2 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones | APOTEX INC. (CA) | 2008-08-12 | — | — | US | disclosed |
| US-20080096886-A1 | Process For The Manufacture Of 3-Hydroxy-N-Alkyl-1-Cycloalkyl-6-Alkyl-4-Oxo-1,4-Dihydropyridine-2-Carboxamide And Its Related Analogues | APOTEX INC. (CA) | 2008-04-24 | — | — | US | disclosed |
| US-20080096886-A1 | Process For The Manufacture Of 3-Hydroxy-N-Alkyl-1-Cycloalkyl-6-Alkyl-4-Oxo-1,4-Dihydropyridine-2-Carboxamide And Its Related Analogues | APOTEX INC. (CA) | 2008-04-24 | — | — | US | disclosed |
| US-20080096886-A1 | Process For The Manufacture Of 3-Hydroxy-N-Alkyl-1-Cycloalkyl-6-Alkyl-4-Oxo-1,4-Dihydropyridine-2-Carboxamide And Its Related Analogues | APOTEX INC. (CA) | 2008-04-24 | — | — | US | disclosed |
| EP-1687298-A4 | CYCLOALKYL DERIVATIVES OF 3-HYDROXY-4-PYRIDINONES | APOTEX INC (CA) | 2007-10-17 | — | — | EP | disclosed |
| EP-1824823-A1 | PROCESS FOR THE MANUFACTURE OF 3-HYDROXY-N-ALKYL-1-CYCLOALKYL-6-ALKYL-4-OXO-1,4-DIHYDROPYRIDINE-2-CARBOXAMIDE AND ITS RELATED ANALOGUES | Apotex Inc. (CA) | 2007-08-29 | — | — | EP | disclosed |
| US-20070082904-A1 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones field of the invention | APOTEX INC. (CA) | 2007-04-12 | — | — | US | disclosed |
| EP-1687298-A1 | CYCLOALKYL DERIVATIVES OF 3-HYDROXY-4-PYRIDINONES | Apotex Inc. (CA) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006053429-A1 | PROCESS FOR THE MANUFACTURE OF 3-HYDROXY-N-ALKYL-1-CYCLOALKYL-6-ALKYL-4-OXO-1,4-DIHYDROPYRIDINE-2-CARBOXAMIDE AND ITS RELATED ANALOGUES | APOTEX INC. (CA) | 2006-05-26 | — | — | WO | disclosed |
| WO-2005049609-A1 | CYCLOALKYL DERIVATIVES OF 3-HYDROXY-4-PYRIDINONES | APOTEX INC. (CA) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170850-A1 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones | HAMP, C1S, C1R | IDH1 264/4885MMP3 1269/4885MMP12 2080/4885 |
| US-20070082904-A1 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones field of the invention | HAMP, C1S, SLC40A1 | IDH1 410/4885MMP3 1293/4885MMP12 1739/4885 |
| US-20080096886-A1 | Process For The Manufacture Of 3-Hydroxy-N-Alkyl-1-Cycloalkyl-6-Alkyl-4-Oxo-1,4-Dihydropyridine-2-Carboxamide And Its Related Analogues | ADH1C, ADH1A, ADH5 | IDH1 23/4885MMP3 3448/4885MMP12 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.